



Emerging Trends in Personalized Medicine in COVID-19

Guest Editor:

Prof. Dr. Kieu C.D. Nguyễn

Department of Interdisciplinary
Medicine, School of Medicine,
University of Bari “Aldo Moro”,
70124 Bari, Italy

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editor

Dear colleagues,

Personalized medicine is an emerging approach for effectiveness in treatment outcomes and toxicity for each COVID-19 patient. Autologous blood plasma and peripheral blood stem cells are a possible treatment for fulminant COVID-19 infection. Personalization has the potential to tailor therapy towards the pharmacogenomics, immunology and immunology genetics drivers of treatment outcome, and thus, on patients' quality of life. Furthermore, this could be the key to avoiding suboptimal drug dosing or adverse events, taking into account the genetic variability of each person, their sex and their age. This Special Issue, “Emerging Trends in Personalized Medicine in COVID-19”, will focus on personalized treatment in COVID-19 and long COVID research, including clinical, preclinical, pharmacological and translational trends.

Dr. Kieu C.D. Nguyễn

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI